ArticleJournal of clinical laboratory analysis2026
Utility of a Combined Diagnostic and Severity Scoring System Based on Complete Blood Count and Derived Immune-Inflammatory Indicators in Children With Mycoplasma pneumoniae Pneumonia.
Article in Journal of clinical laboratory analysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThis study assessed the diagnostic value of complete blood count (CBC) and derived immune-inflammatory indicators for Mycoplasma pneumoniae pneumonia (MPP) in children and developed a practical scoring system for early diagnosis.
methodsA total of 1662 MP-infected children were divided into pneumonia (n = 844) and non-pneumonia (n = 818) groups. CBC parameters, derived immune-inflammatory indicators and C-reactive protein (CRP) were compared. Diagnostic performance was assessed using ROC curve analysis, and diagnostic models were constructed using multivariate logistic regression. Age-stratified analysis addressed confounding. Model stability was evaluated via repeated stratified 10-fold cross-validation, calibration curves with Brier score, and decision curve analysis (DCA). A simplified scoring system was established and validated for clinical application.
resultsChildren in the pneumonia group were significantly younger (mean age 5.78 ± 3.41 years vs. 8.62 ± 4.92 years, p < 0.001). Lymphocyte count (LYM), lymphocyte percentage (LYM%), platelet count (PLT), plateletcrit (PCT), and the product of absolute lymphocyte count and platelet count (PLT × LYM) in the pneumonia group were significantly higher than in the non-pneumonia group. Age-stratified analysis confirmed these differences across all age subgroups (all p < 0.001). PLT × LYM, LYM%, PLT, and PCT were independent predictors. Internal validation showed a mean AUC of 0.7824 ± 0.0353, good calibration (Brier score = 0.1918 ± 0.0164), and positive net benefit on DCA. The scoring system achieved diagnostic rates of 71.5%, 51.2%, and 29.6% for high-, medium-, and low-risk groups, respectively.
conclusionMPP predominantly affects children under 7 years old. The simple scoring system, supported by robust internal validation, effectively stratifies pneumonia risk and offers a practical early diagnostic tool for primary care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.